GlassScriptPhysician profile
Seong G Bae
NPI 1114122769
$16,087.89
in general payments reported to CMS, 2019-2025
29 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 80% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $1,033 · 2021: $12K · 2022: $498 · 2023: $87.43 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $292.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,653.73 | 2019-2025 | |
| Davol INC. | $191.51 | 2019-2025 | Phasix Mesh |
| Karyopharm Therapeutics INC. | $154.78 | 2021-2023 | Xpovio |
| Acell, INC. | $134.23 | 2020 | |
| Seagen INC. | $98.01 | 2019-2021 | |
| Amgen INC. | $94.86 | 2021-2022 | |
| Taiho Oncology, INC. | $72.39 | 2020-2021 | |
| Incyte Corporation | $70.55 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.25 | 2021-2023 | |
| Innocoll Pharmaceuticals Limited | $56.34 | 2022 | |
| Baxter Healthcare | $48.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.44 | 2019-2025 | |
| Eisai INC. | $38.16 | 2021-2022 | |
| G1 Therapeutics, INC. | $38.05 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.99 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.78 | 2022-2023 | Lynparza, Keytruda |
| Blueprint Medicines Corporation | $25.00 | 2021 | |
| Ge Healthcare | $24.63 | 2021 | |
| Genzyme Corporation | $24.13 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.86 | 2021 | |
| Cti Biopharma Corp. | $21.81 | 2023 | Vonjo |
| Tesaro, INC. | $20.90 | 2019 | |
| Puma Biotechnology, INC. | $20.01 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $17.73 | 2021 | |
| Kyowa Kirin, INC. | $17.52 | 2019 | |
| Aveo Pharmaceuticals, INC. | $16.30 | 2021 | |
| Tela Bio, INC. | $16.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seong Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.